Gilead Extends Arcellx Tender to April 24, Finalizing $7.8B Deal with CVR; HIV Drug Coverage Varies
GILD sits 49% above its 52-week low of $93.37.
Summary
Gilead Sciences has extended its tender offer for Arcellx to April 24, 2026, finalizing the acquisition at an updated value of approximately $7.8 billion. This deal includes $115 cash per share plus a contingent value right (CVR) of up to $5, tied to anito-cel sales reaching $6 billion by 2029. This update provides specific financial terms and a timeline for the acquisition, which was previously disclosed in the company's 10-K as a $7.0 billion deal. Separately, the company faces challenges with its long-acting HIV prevention injection, as its coverage is not explicitly included in the 2023 U.S. task force guidance, leading to varied insurer coverage and patient out-of-pocket costs. Traders should monitor the closing of the Arcellx deal and the company's efforts to secure broader reimbursement for its HIV prevention product, as market access issues could impact future revenue.
At the time of this announcement, GILD was trading at $139.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $173.4B. The 52-week trading range was $93.37 to $157.29. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.